Apollo Capital comments on Medipharm’s failure to respond to offer

Apollo Technology Capital Corporation, which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs (MEDIF), owning approximately 3% of the Company’s common stock, announced that MediPharm Labs’ Board of Directors did not respond to Apollo Capital’s “With Prejudice” offer to the Board to ensure the rights of shareholders are protected in connection with the Company’s upcoming 2025 Annual and Special Meeting of Shareholder to be held on June 16, 2025. Apollo Capital distributed the offer to MediPharm Labs counsel on May 21, 2025 – seeking to ensure a lawful and fair election overseen by an independent Chair in order to protect the rights of shareholders at the Annual Meeting. The offer, which Apollo Capital shared publicly, was unilaterally ignored by MediPharm Labs’ Board, who made no attempts whatsoever to engage with representatives of Apollo Capital. Apollo Capital Chairman and CEO Regan McGee commented, “MediPharm Labs and its Board continue to demonstrate their utter disregard for the rights of shareholders, preferring to further entrench themselves rather than honour their fiduciary duty to act in shareholders’ best interests. Apollo Capital’s offer was made in good faith to take the necessary steps to do right by MediPharm Labs shareholders, and it is damning that the Board would put its own personal interests ahead of the law and the interests of Company shareholders. The record needs to be set straight after all the misleading, defamatory and demonstrably untrue statements from the MediPharm Labs Board. Outside of MediPharm Labs, all litigation that I am involved in is related to each other. It is effectively one litigation and was initiated by me in order to protect shareholders from a small group of rogue board members who I sued for breaching their fiduciary duties. Tellingly, but not surprisingly, the MediPharm Labs Board wants to suggest that this is somehow a bad thing! The Company’s attempts to villainize me are merely a feeble attempt to misdirect shareholders away from legitimate concerns regarding their staggering mismanagement of MediPharm Labs, which they have yet to answer for.”